RE:RE:RE:RE:RE:articleI'm aware of the number from Doug Loe' latest analysis. But that 188M U$ (or 254M U$) is an annual revenue...and our friend Hatchat is talking of a market cap of 180 millions.
For a pharma with a high margin % product (like MCNA), the market cap is usually at least 10 the revenue. Exactly why the number he mentionned (market cap of 180M Can$ or a SP of 60 cents) is completely off-track (if the FDA gives any kind of approval).
By the way, the FDA didn't set the primary endpoint of a DFS of 40 % at one year, for the study 301 (phase 3). TST set the bar that high themselves after promising phase 2 results. It was recognized a few years ago that these numbers were not realistic for high-risk BCG refractory patients. And that a DFS of 30 % at one year would be clinically significant. TST did meet that number in their phase 3 results (low-grade tumors recurrence is now considered as a disease-free state according to new standard)...when considering this new definition for the group of 129 patients, DFS @ 1 year with MCNA was slighty over 30 %.
M80